Clinical Trial

Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn about the safety and side effects of intralesional collagenase clostridium histolyticum (CCH) injected into the Peyronies Disease (PD) plaque after receiving prior treatment with intralesional Platelet Rich Plasma (PRP) injections.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-05
notable Enrollment reduced: 22 -> 12 participants 2026-06-05
Trial Details
NCT Number NCT05777031
Lead Sponsor University of Miami
Collaborators: Endo USA Inc., a Keenova Therapeutics Company
Conditions Peyronie Disease, Sexual Dysfunctions, Psychological, Genital Diseases, Male
Enrollment 12 participants
Start Date 2023-10-02
Primary Completion 2027-01-15 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-04